

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ronald C. Fedus on 8/11/08.

The application has been amended as follows:

In the **Specification**:

On Page 10, amend the Brief Description of Figure 2 as follows:

FIGURE 2 shows the wild type 3' LTR native sequence that was removed from the plasmid pENZ1 as well as the non-native modified 3' LTR sequence that replaced it (SEQ ID NO:15 and 16). The modified sequences are designated by bold italics.

On Page 42, after

"the lac repressor of E. coli,

TGGAAT TGTGAGCGGATAACAATT

ACCTTAACACTCGC CTATT GTTAA;" insert --(SEQ ID NO:5)--.

On Page 43, after

"the CAP gene activator of E. coli

Art Unit: 1636

AAAAGTGTGACAT

TTT T CACACTGTA;" insert --(SEQ ID NO:8)--.

On Page 43, after

"the GAL4 yeast transcription activator,

CCGGAGGACAG

GGCCTCCT GTC;" insert --(SEQ ID NO:9)--.

On Page 43, after

"the E2 papillomavirus transcription regulator,

ACCGACGTCGGT

TGGCTGCAGCCA;" insert --(SEQ ID NO:10)--.

On Page 46, after "filed on May 5, 1983," insert --now abandoned--.

Please amend the **Abstract** as follows:

Abstract of the Disclosure

Provided are novel vectors and viral vectors capable of expressing exogenous gene or exogenous nucleic acid sequences in a target cell of interest, such as T cells, bone marrow cells, epithelial cells, liver cells and the like. The nucleic acid components of the vectors may include one or more native promoter/enhancer regions having modified sequence segments, one or more non-native promoter/enhancer or non-native promoter's gene or gene segment, and a native viral vector terminator or processing signal or segment thereof. The viral vectors comprise a virus or viral portion having on the surfaces or envelopes adsorption components, one for a packaging cell line and the other for delivery to a target cell. ~~Other viral vectors provided by this invention have two components on their surfaces or envelopes, one of which is native to the virus and the other being non-native and capable of adsorbing to the target cell while being incapable of adsorbing to a native cell for the viral vector.~~ Packaging cell lines for propagating the vectors and viral vectors are also provided, as are novel processes for propagating any of the disclosed vectors or viral vectors.

Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach, Ph.D., can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

August 12, 2008

/David Guzo/
Primary Examiner
Art Unit 1636